Falcon Pharmaceuticals, Ltd. company specializes in making generic equivalents of ophthalmic drugs that treat a range of eye conditions, as well as otic (ear) and nasal ailments. Its lead product, Timolol GFS, is a generic equivalent of Merck's glaucoma treatment Timoptic-XE gel. Falcon Pharmaceuticals company also offers anti-infective, steroid, anti-viral, anti-allergy, and anesthetic pharmaceutical products without the markup typically associated with brand names. Falcon Pharmaceuticals is a subsidiary of eye care products company Alcon.

Zila, Inc., a diagnostic company, engages in the prevention, detection, and treatment of oral cancer and periodontal disease. It manufactures and markets ViziLite Plus with TBlue, its flagship product, for early detection of oral abnormalities that could lead to cancer. In addition, the company designs, manufactures, and markets a suite of proprietary products directly to dental professionals for periodontal disease, including the Rotadent Professional Powered Brush, the Pro-Select Platinum ultrasonic scaler, and a portfolio of oral pharmaceutical products for in-office and home-care use. Further, it had certain technology rights, and the United States and foreign patent rights related to the OraTest, an oral cancer diagnostic product. Zila, Inc. markets and sells its products in the United States and Canada through direct sales force, and internationally through third party distributors. The company was founded in 1980 and is headquartered in Phoenix, Arizona. As of September 18, 2009, Zila, Inc. operates as a subsidiary of Tolmar, Inc.

Photopharmica Ltd. discovers and develops photo sensitizers and light sources for medical use in the United Kingdom. The company develops anti-infective agents primarily for dermatology and wound management markets; and medical devices in the fields of orthopedics and periodontal equipment. Its products pipeline includes phenothiazinium photo sensitizers for use as topical therapeutic antimicrobial agents; phenothiazinium photo sensitizers for systemic oncology use; and phthalocyanine photo sensitizers that combine anti-tumor properties with minimal or zero skin photo sensitization. Photopharmica Ltd. was founded in 2001 and is based in Leeds, the United Kingdom.

GenVec, Inc. company was founded in 1992 and is based in Gaithersburg, Maryland. GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III trial for first-line treatment of inoperable, locally advanced pancreatic cancer. The company is also evaluating TNFerade biologic, wfor the treatment of various cancers, including esophageal cancer, rectal cancer, and head and neck cancer. In addition, it is developing TherAtoh, a preclinical program involving the delivery of the human atonal gene for the production of therapeutic proteins by cells in the inner ear. Further, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases, including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and HSV-2. It has strategic alliances and research contracts with the U.S. department of homeland security, the U.S. department of agriculture, PATH'S malaria vaccine initiative, the U.S. naval medical research center, and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

Vertex Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, Massachusetts. Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Its product pipeline includes Telaprevir, a Phase III clinical trial product for the treatment of hepatitis C virus (HCV) infection; VX-813, a Phase Ia clinical trial product for chronic HCV infection; VX-985, which is under preclinical trails for chronic HCV infection; VX-770, a Phase IIa clinical trial candidate for the treatment of Cystic fibrosis; VX-809, a Phase Ib clinical trial product for the treatment of Cystic fibrosis; VX-509, a Phase Ia clinical trial product for immune-mediated inflammatory diseases; MK-5108 (VX-689), a Phase I clinical trial product for the treatment of cancer; and AVN-944(VX-944), which is in Phase 2 clinical trial for the treatment of cancer. The company also has development and commercial rights to VX-702 for the treatment of rheumatoid arthritis and other inflammatory diseases. It has collaboration agreements with Janssen Pharmaceutica, N.V.; Mitsubishi Tanabe Pharma Corporation; Cystic Fibrosis Foundation Therapeutics Incorporated; Merck & Co., Inc.; Avalon Pharmaceuticals, Inc.; GlaxoSmithKline plc.; and Bend Research Inc.

Vical Incorporated was founded in 1987 and is based in San Diego, California. Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent development programs in the areas of infectious disease and cancer. These are a Phase III clinical trial using its Allovectin-7 immunotherapeutic in patients with metastatic melanoma; a Phase II clinical trial using its cytomegalovirus (CMV) DNA vaccine in hematopoietic cell transplant patients, and a Phase I clinical trial using its H5N1 pandemic influenza DNA vaccine formulated with its Vaxfectin adjuvant.

Antigenics was founded in 1994 and is headquartered in Lexington, Massachusetts. Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its products include Oncophage (vitespen), a patient-specific therapeutic cancer vaccine registered for use in the Russia Federation, as well as under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. The company tested Oncophage in phase 3 clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and phase 1 and phase 2 clinical trials for various indications, as well as in phase 2 clinical trial for the treatment of recurrent glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is used in various vaccines under development in trials for diseases, such as hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer's disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics, Inc. in February 2000.

Calyx Bio-Ventures (formerly Chromos Molecular Systems) wants you to part with that chromosome. The company is developing therapeutic products to fight diseases based on its REM (rapid expansion method) technology. The company has sold its ACE System (artificial chromosome expression) technology but retains some rights to use the ACE System for gene therapy applications. The system's potential biopharmaceutical product applications include therapies for infectious diseases and cancers. The company emerged from bankruptcy protection in late 2007 and completed its restructuring when it merged its operations into its Calyx subsidiary the following year.

Progenics Pharmaceuticals, Inc. company was founded in 1986 and is based in Tarrytown, New York. Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. The company, in collaboration with Wyeth Pharmaceuticals, provides RELISTOR-Subcutaneous injection for the treatment of opioid-induced constipation (OIC) in advanced illness patients receiving palliative care. It is also developing the HIV entry inhibitor, PRO 140, a humanized monoclonal antibody targeting the entry co-receptor, CCR5, and is in Phase II clinical testing; and a novel HCV entry inhibitor, PRO 206. In addition, Progenics Pharmaceuticals is conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate (ADC) designed to selectively target prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as in blood vessels supplying non-prostatic solid tumors; and various Phase I clinical trials with vaccines designed to treat prostate cancer by stimulating an immune response to PSMA.

Phenomix hopes to create a pharmaceutical phenomenon by investigating and discovering new treatments for immune system ailments and metabolic diseases. The drug development company's lead product candidate dutogliptin is an oral-dose treatment aiming to stabilize glucose levels in patients with Type 2 diabetes. Other pipeline candidates target infectious and autoimmune diseases, including hepatitis C and certain types of cancer. The biotechnology firm's drug candidates focus on inhibiting complex proteins (enzymes) that promote disease within the body. The company is owned by a number of private investors.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.